Merck KGaA (MRK) Given a €108.00 Price Target by UBS Group Analysts

Merck KGaA (FRA:MRK) received a €108.00 ($125.58) target price from equities research analysts at UBS Group in a research report issued to clients and investors on Monday, April 1st, Borsen Zeitung reports. The firm presently has a “neutral” rating on the healthcare company’s stock. UBS Group’s target price would suggest a potential upside of 11.69% from the company’s current price.

MRK has been the subject of a number of other reports. Kepler Capital Markets set a €108.00 ($125.58) target price on shares of Merck KGaA and gave the stock a “buy” rating in a report on Tuesday, February 12th. JPMorgan Chase & Co. set a €100.00 ($116.28) price objective on shares of Merck KGaA and gave the stock a “neutral” rating in a research note on Tuesday, February 12th. Sanford C. Bernstein set a €105.00 ($122.09) price objective on shares of Merck KGaA and gave the stock a “buy” rating in a research note on Thursday, January 3rd. HSBC set a €96.00 ($111.63) target price on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Monday, March 11th. Finally, Barclays set a €78.00 ($90.70) target price on shares of Merck KGaA and gave the stock a “sell” rating in a research report on Tuesday, January 15th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of €101.00 ($117.44).

Shares of FRA:MRK opened at €96.70 ($112.44) on Monday. Merck KGaA has a 52 week low of €76.60 ($89.07) and a 52 week high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Read More: Moving Average – How it Helps Investors in Stock Selection

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.